Boston Scientific (BSX) Non-Current Deferred Tax Liability (2009 - 2026)

Boston Scientific (BSX) has 18 years of Non-Current Deferred Tax Liability data on file, last reported at $219.0 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deferred Tax Liability rose 38.61% year-over-year to $219.0 million; the trailing twelve-month figure through Mar 2026 stood at $219.0 million (up 38.61% YoY), and the FY2025 full-year result was $220.0 million, up 41.94% from the prior year.
• Non-Current Deferred Tax Liability was little changed at $219.0 million in Q1 2026, from $220.0 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $278.0 million in Q3 2022 to a low of $91.0 million in Q3 2023.
• A 5-year average of $182.8 million and a median of $158.0 million in 2025 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability jumped 130.43% in 2022 and plunged 67.27% in 2023, its largest moves.
• Tracing BSX's Non-Current Deferred Tax Liability over 5 years: stood at $144.0 million in 2022, then decreased by 29.17% to $102.0 million in 2023, then jumped by 51.96% to $155.0 million in 2024, then jumped by 41.94% to $220.0 million in 2025, then decreased by 0.45% to $219.0 million in 2026.
• Business Quant data shows BSX's Non-Current Deferred Tax Liability at $219.0 million in Q1 2026, $220.0 million in Q4 2025, and $242.0 million in Q3 2025.